This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Bristol-Myers Squibb To Present Data On Rheumatoid Arthritis Assets At American College Of Rheumatology (ACR) 2013 Annual Meeting

Stocks in this article: BMY

Bristol-Myers Squibb Company (NYSE: BMY) announced today that 20 abstracts have been accepted for presentation at the 2013 annual meeting of the American College of Rheumatology (ACR) taking place from October 25-30 in San Diego, CA. The breadth of data underscores the Company’s continued commitment to develop medicines that address the unmet medical needs of patients suffering from rheumatic and other immune-mediated diseases.

Key presentations include:

  • The first presentation of efficacy and safety results from a Phase IIb study of subcutaneous (SC) clazakizumab, an investigational anti-IL-6 monoclonal antibody, in adults with moderate-to-severe rheumatoid arthritis (RA) and an inadequate response to methotrexate. Bristol-Myers Squibb has exclusive worldwide rights to develop and commercialize clazakizumab for all indications outside of cancer under a collaboration agreement with its discoverer, Alder Biopharmaceuticals.
  • Results from the two-year AMPLE trial of Orencia ® SC (abatacept) and Humira ® (adalimumab) in biologic-naive RA patients, including efficacy, safety and patient-reported outcomes data.
  • More than 10 health economics and outcomes research presentations that add to the collective understanding of real-world use of RA medications and the costs associated with treatment.

“Bristol-Myers Squibb will continue its long standing commitment to immunoscience research and to a strong culture of innovation to help further advancements in the treatment of immune-mediated diseases like RA,” said Michael Giordano, senior vice president, Head of Development, Oncology and Immunology, Bristol-Myers Squibb. “The data and findings we are presenting at the ACR annual meeting demonstrate our commitment to pre-clinical, clinical, and real world and health outcome research to help patients.”

The complete list of Bristol-Myers Squibb presentations is below. Abstracts can be accessed on the ACR website at https://ww2.rheumatology.org/apps/MyAnnualMeeting/.

Title   Date/Time
CLAZAKIZUMAB  
A Phase IIb Study Of The Efficacy and Safety Of Subcutaneous Clazakizumab (anti-IL-6 monoclonal antibody) With Or Without Methotrexate In Adults With Moderate-To-Severe Active Rheumatoid Arthritis and An Inadequate Response To Methotrexate Oral Presentation

October 28

2:30 - 4 pm

Anti-IL-6 Antibody Clazakizumab Is More Potent Than Tocilizumab In Blocking In Vitro and Ex Vivo IL-6-Induced Functions October 29
ORENCIA (Abatacept)  
Head-To-Head Comparison of Subcutaneous Abatacept Versus Adalimumab on Background Methotrexate in RA: Two Year Results from the AMPLE Study October 29
2-Year Results from the AMPLE (Abatacept versus Adalimumab Comparison in Biologic-Naïve RA Patients with Background Methotrexate) Trial: Changes in Patient-Reported Outcomes in Response to Subcutaneous Abatacept or Adalimumab in Rheumatoid Arthritis October 27
Effects of SC Abatacept or Adalimumab on Remission and Associated Changes in Physical Function and Radiographic Outcomes: Two Year Results from the AMPLE Trial October 27
Abatacept or anti-TNF monoclonal antibodies: Efficacy and safety comparisons October 29
Antibody response to pneumococcal and influenza vaccination in patients with RA receiving subcutaneous abatacept October 27
Adherence to the Recommended Dosing Regimen of Abatacept in the Real-world Setting in the ACTION Study: Is There a Dose-creep in Overweight Patients? October 28
Gene expression in whole blood predicts the abatacept-methotrexate combination responsiveness in rheumatoid arthritis: preliminary results October 29
Abatacept is highly effective at inhibiting T cell priming and induces a unique transcriptional profile in CD4+ T cells October 27
Pilot Study of Abatacept in Patients with Refractory Autoimmune Chronic Urticaria October 29
DISEASE-STATE PRESENTATIONS  
Musculoskeletal Hospital Admissions Among Patients Treated For Rheumatoid Arthritis Between 1999 and 2010 Compared With The General Population In The Netherlands October 27
Evaluation Of Hospitalizations and Costs In Patients With Rheumatoid Arthritis In United States Medicare Population October 28
Analysis Of Non-Steroidal Anti-Inflammatory Drug Burden Among Rheumatoid Arthritis Patients Using The Dougados Algorithm October 27
Biologic Switching Rates among Patients with Rheumatoid Arthritis in Medicare October 29
Rates of Switching and Healthcare Costs Associated with Switching Biologic Disease-modifying Antirheumatic Drugs in a Commercial Population: Evidence from Real-world Observational Studies October 28
Outcomes of patients with rheumatoid arthritis and comorbid hyperlipidaemia October 27
Prevalence of Systemic Lupus Erythematosus and Lupus Nephritis in the United States: Analysis of Commercial and Public Insurance Billing Data October 28
Coronary endothelial dysfunction directly measured by N13 Positron Emission Tomography (PET) is detected in established Rheumatoid Arthritis (RA), but not early RA October 27
Assessing Validity Of Low Field Magnetic Resonance Imaging (MRI) for Joint Inflammation and Damage In Wrist/Hand Rheumatoid Arthritis (RA) - A Systematic Literature Review (SLR) October 29

About Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a systemic, chronic, autoimmune disease characterized by inflammation in the lining of joints (or synovium), causing joint damage with chronic pain, stiffness, swelling and fatigue. RA causes limited range of motion and decreased joint function. The condition is more common in women than in men, who account for 75% of patients diagnosed with RA.

About Orencia ® (abatacept)

Orencia subcutaneous (SC) injection and intravenous (IV) infusion are indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. Orencia may be used as monotherapy or concomitantly with disease-modifying antirheumatic drugs (DMARDs) other than tumor necrosis factor (TNF) antagonists.

Orencia IV is indicated for reducing signs and symptoms in pediatric patients 6 years of age and older with moderately to severely active polyarticular juvenile idiopathic arthritis. Orencia IV may be used as monotherapy or concomitantly with methotrexate (MTX). Orencia SC has not been studied in pediatric patients.

Orencia should not be administered concomitantly with TNF antagonists.

Orencia is not recommended for use concomitantly with other biologic rheumatoid arthritis (RA) therapy, such as anakinra.

Orencia is intended for use under the guidance of a physician or healthcare practitioner.

Indication/Usage and Important Safety Information for ORENCIA ® (abatacept)

Indication/Usage

Adult Rheumatoid Arthritis (RA): ORENCIA ® (abatacept) is a prescription medicine that reduces signs and symptoms in adults with moderate to severe rheumatoid arthritis (RA), including those who have not been helped enough by other medicines for RA. ORENCIA may prevent further damage to your bones and joints and may help your ability to perform daily activities. In adults, ORENCIA may be used alone or with other RA treatments other than tumor necrosis factor (TNF) antagonists.

Juvenile Idiopathic Arthritis (JIA): ORENCIA also reduces signs and symptoms in children and adolescents 6 years of age and older with moderate to severe polyarticular juvenile idiopathic arthritis (JIA). ORENCIA may be used alone or with methotrexate (MTX).

Important Safety Information About ORENCIA ® (abatacept)

Inform your healthcare provider of the following, before you receive treatment with ORENCIA:

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,570.77 +171.10 1.04%
S&P 500 1,932.11 +28.10 1.48%
NASDAQ 4,390.5120 +74.4380 1.72%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs